ArticleCardiovascular endocrinology & metabolism2025
BRIDGE-DS study: evaluating the effectiveness and safety of dapagliflozin/sitagliptin combination in type 2 diabetes mellitus patients with heart failure.
Article in Cardiovascular endocrinology & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Co-occurrence of type 2 diabetes mellitus (T2DM) and heart failure (HF) elevates the risk of morbidity and mortality. Recent research emphasizes treatment strategies that go beyond glycemic control to enhance heart function. Aim: To assess the effectiveness and safety of the fixed-drug combination of dapagliflozin and sitagliptin (FDC D/S) in T2DM patients with HF. Methods: This was a retrospective, multicenter, observational study that included data from 168 T2DM patients with HF receiving treatment with FDC D/S. Outcome parameters included glycated hemoglobin (HbA Results: The mean age of the patients was 55.5 ± 10.5 years. Most patients had comorbidities such as hypertension (86.3%) and dyslipidemia (75%), with more than 53% being obese. A significant ( Conclusion: FDC D/S enhances glycemic control in T2DM patients with HF, leading to reductions in HbA
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.